Hongbo Lu bought $6.0M of Zenas BioPharma (ZBIO)
Executed Sep 13 2024, disclosed Oct 9 2025, 391 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Oct 9 2025), the stock returned +23.8% (delay-adjusted); from the execution session (Sep 13 2024), -5.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Hongbo Lu (Director) filed 4 Form 4 reports in the trailing twelve months (3 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in Zenas BioPharma, Inc. (ZBIO). Across 3 priced purchase filings, the average 21-session return was +1.6% from execution and +2.9% from disclosure (delay-adjusted; derived). The largest single filing was $1.5M of ZBIO (75,000 sh × $20.00, as filed), executed Mar 31.
Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→75,000 sh × $20.00
Exec Mar 31
Filed Mar 31 · 5:00 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. $585K
25,985 sh × $22.50
Exec Feb 11
Filed Feb 13 · 5:35 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. $1000K
58,823 sh × $17.00
Exec Sep 13 2024
Filed Sep 17 2024 · 5:30 PM ET